The biotech space is not for the faint hearted, given the ebbs and flows in terms of the returns from investing in it. However, for one who perseveres and astutely devises strategies with full cognizance of key regulatory events coming up, the probability of drug candidates getting FDA’s blessings and sympathy plays in the space, it provide a sea of opportunity and huge upside prospects.
As per a study by the Economic Policy Institute, compensation for top CEOs in 2014 averaged $16.3 million, which was 303 times more than that of a typical worker.
While just about every country in the world depends on oil, not all countries produce it. The top ten countries accounted for more than 64 percent of the world’s oil production.
Drug companies spend billions on R&D, which is the lifeline of the pharma industry. According to a report published by the Tufts Center for the Study of Drug Development, it costs about $2.6 billion to develop a new drug and bring it to market.